1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1636
  6. Examiner Chong

Examiner Chong Kimberly

1636-CHONG-KIMBERLY

Employment Information

Art Unit:1636 — Chemistry: molecular biology and microbiology
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 514 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
435 — Chemistry: molecular biology and microbiology
424 — Drug, bio-affecting and body treating compositions
506 — Combinatorial chemistry technology: method, library, apparatus
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
436 — Chemistry: analytical and immunological testing
Phone:(571) 272-3111
Email:kimberly.chong@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:22 years
Grade:GS-14

Grant Rate and Difficulty Ranking

65
3-Year Grant rate: 67% over 686 cases
Difficulty: Harder
Difficulty Percentile: 65th

With Examiner Chong, you have a 67% chance of getting an issued patent by 3 years after the first office action. Examiner Chong is a harder examiner and in the 65th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Chong, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1636

Examiner Chong's grant rate is higher than that of Art Unit 1636 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Chong 1.5
Art Unit 1636 1.9

Interview Benefit

Grant Rate without Interview

Examiner Chong has granted 351 of 555 cases without any applicant-requested interviews for a grant rate of 63%.

Grant Rate with Interview

Examiner Chong has granted 112 of 131 cases with at least one applicant-requested interview for a grant rate of 85%.

Interview Benefit

With Examiner Chong, conducting an interview increases your chance of getting a patent granted by 35%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17778567 Methods And Compositions For Neuroprotection Rejection information available with a Premium Stats subscription. See our pricing. Patented View
19054728 Translation Enhancing Nucleic Acid Compounds: Aso Coupled Translation – Upregulation 1 (Act-Up1) And Uses Thereof Patented View
17749039 Immunomodulatory Rna Patented View
18854213 Methods Of Identifying Cancers Having A Biallelic Loss Of Function Mutation Abandoned View
18330590 Non-Liposomal Systems For Nucleic Acid Delivery Abandoned View
19052052 Methods And Compositions For Treatment Of Polycystic Kidney Disease Patented View
18163506 Nucleic Acid Complex Abandoned View
17898947 Compositions Comprising Circular Polyribonucleotides And Uses Thereof Patented View
17280411 Treating Atopic Dermatitis By Targeting The Wnt Pathway Patented View
18152504 Single-Stranded Oligonucleotide Abandoned View
17442663 Double-Stranded Nucleic Acid Complex And Use Thereof Abandoned View
18429059 Assays And Methods To Assist In Vitro Fertilization Patented View
18660147 Compositions And Methods Of Treating Facioscapulohumeral Muscular Dystrophy Patented View
17789750 Antisense Oligonucleotides For Treatment Of Neurological Disorders Abandoned View
17986023 Methods And Compositions For The Adar-Mediated Editing Of Argininosuccinate Lyase (Asl) Abandoned View
17970887 Compositions And Methods For Modulating Ttr Expression Patented View
17910574 Gene Replacement Therapy For Foxg1 Syndrome Patented View
17908199 Antisense Oligonucleotides For Use In The Treatment Of Usher Syndrome Abandoned View
17843657 Products And Compositions Abandoned View
17984486 Short Interfering Nucleic Acid (Sina) Compositions Patented View
17788826 Antisense Nucleic Acid That Induces Skipping Of Exon 50 Abandoned View
18053559 Treatment Of Fuchs' Endothelial Corneal Dystrophy Patented View
19010571 Small Rna-Based Drug, Preparation And Use Thereof In Prophylaxis And/or Treatment Of Cardiomyopathy Patented View
18065086 Splicing-Dependent Transcriptional Gene Silencing Or Activation Patented View
17755943 Il-34 Antisense Agents And Methods Of Using Same Abandoned View
16955596 Double-Stranded Dna Molecule For The Detecting And Characterizing Molecular Interactions Patented View
18301040 Micrornas And Methods Of Their Use Abandoned View
18202328 Polynucleotide Agents Targeting Programmed Cell Death 1 Ligand 1 (Pd-L1) And Methods Of Use Thereof Abandoned View
17626981 Melanophilin Antisense Oligonucleotides Abandoned View
17271496 Compositions And Methods For Detecting Antibiotic Responsive Mrna Expression Signatures And Uses Thereof Patented View
17090804 Differential Knockout Of An Allele Of A Heterozygous Elane Gene - Ii Patented View
17936820 Microrna And Uses Thereof In Prevention And/or Treatment Of Fibroplasia Medical Sign And/or Syndrome Patented View
17293452 Asparaginase Therapeutic Methods Abandoned View
18032845 Antimicrobial Biosensors Abandoned View
17596764 Combination Of Hepatitis B Virus (Hbv) Vaccines And Hbv-Targeting Rnai Abandoned View
16966965 Compositions And Methods For Gene Editing By Targeting Fibrinogen-Alpha Abandoned View
17523030 Coronavirus Irna Compositions And Methods Of Use Thereof Patented View
17719019 Adeno-Associated Virus Vector Delivery Of Microrna-29 To Treat Muscular Dystrophy Abandoned View
17810495 Circulating Microrna Signatures For Ovarian Cancer Patented View
16638107 Conditional-Sirnas And Uses Thereof In Treating Cardiac Hypertrophy Patented View
18156360 Rna Interactome Of Polycomb Repressive Complex 1 (Prc1) Abandoned View
17305225 Multimeric Oligonucleotides Having Decreased Kidney Clearance Patented View
17411460 Treatment Of Sepsis With Pcsk9 And Ldlr Modulators Patented View
17721530 Complement Component C3 Irna Compositions And Methods Of Use Thereof Patented View
17364765 Nucleic Acid-Polypeptide Compositions And Uses Thereof Patented View
16772678 Compositions Comprising Circular Polyribonucleotides And Uses Thereof Patented View
18281523 A Method For Assessing The Potential Effect Of Therapeutics On An Individual Abandoned View
18147549 Reducing Beta-Catenin Expression To Potentiate Immunotherapy Abandoned View
17867929 Methods Relating To Lung Cancer Patented View
18086209 Sirt1-Sarna Compositions And Methods Of Use Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.